Cyberounds Logo
November 17, 2019 | LOGIN | REGISTER | HELP | 


email a friend print Bookmark and Share
Molecular Mechanisms of Cognitive Deficits in Schizophrenia
CME credit is no longer available for this conference.
Sarah Canetta, Ph.D., and Christoph Kellendonk, Ph.D.

Dr. Canetta is Associate Research Scientist and Dr. Kellendonk is Assistant Professor of Pharmacology (in Psychiatry), Departments of Psychiatry & Pharmacology, Columbia University, and the Division of Molecular Therapeutics, New York State Psychiatric Institute, New York.

Within the past 12 months, Drs. Canetta and Kellendonk have no conflicts of interest relevant to this activity.

Albert Einstein College of Medicine, CCME staff, and interMDnet staff have nothing to disclose relevant to this activity.


Release Date: 05/02/2016
Termination Date: 05/02/2019

Estimated time to complete: 1 hour(s).

Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 
Learning Objectives
Upon completion of this Cyberounds®, you should be able to:
  • Describe aspects of cognitive functioning that are impaired in schizophrenia, with a particular focus on prefrontal cortex-dependent domains such as working memory and attentional set-shifting;
  • Delineate several major elements of the neural circuitry that contribute to working memory and attentional set-shifting under normal conditions and that may be compromised in schizophrenia;
  • Describe several of the neuromodulatory systems within the prefrontal cortex that contribute to working memory and attentional set-shifting under normal conditions and that may be compromised in schizophrenia;
  • Discuss several emerging areas of therapeutics to treat cognitive dysfunction in schizophrenia.

 
The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
 
Please click below to accept the terms of this CME activity